AUPH SEC Filing News — Aurinia Pharmaceuticals Inc.

Latest SEC filings for Aurinia Pharmaceuticals Inc. (AUPH) explained in plain English. Covers insider buying and selling (Form 4), proposed insider sales (Form 144), material company events (8-K), and quarterly & annual reports (10-Q / 10-K). StrongBuyAnalytics provides navigation and brief excerpts or summaries; original filings remain at the SEC/source links and were authored by their filers, not StrongBuyAnalytics. Filing dates shown are source dates. Coverage and detection can be delayed or incomplete because of SEC availability, amendments, parsing, caching, or outages. Latest source filing date shown: 2026-09-11.

Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. It also develops aritinercept, a dual inhibitor of B cell-activating factor and proliferation-inducing ligand for the potential treatment of autoimmune diseases. The company was fou…
Sector: Healthcare Industry: Biotechnology Market Cap: $2.2B
20
Total Filings
1
Bullish Classifications
5
Bearish Classifications
10
Insider Transactions
3
Material Events (8-K)
1
Periodic Reports
Rule-based classifications for AUPH currently lean bearish. Of the 20 filing records displayed, 5 carry bearish classifications (such as insider sales or negative 8-K disclosures) versus 1 bullish. This does not necessarily signal fundamental deterioration — insiders sell for many reasons — but it is worth monitoring alongside the company's core financial metrics.
AUPH Filing Activity Snapshot 2026-05-11 — 2026-09-11
Insider Transactions (Form 4)
1 buy vs 2 sells
Net insider selling in this period — insiders sell for many reasons beyond conviction.
Largest Form 144 Filing
$54.10M
GREGORY KEENAN · 2026-06-02
25,000 shares · Form 144
Form 144 Notices
6
Proposed insider sales filed — Form 144 is a notice of intent, not a confirmed transaction. Actual sales are confirmed via Form 4.
Insider Transactions 10 · Forms 3, 4 and 5

A Form 4 is filed within two business days of a company insider — an officer, a director, or a holder of more than ten percent of the stock — changing their position in the shares. All 10 filings in this group are Form 4s for Aurinia Pharmaceuticals Inc.

The difficulty with reading these filings as a group is that a single form type covers transactions that mean entirely different things. An executive spending their own money to buy stock and an executive having shares withheld to pay tax on a vesting grant both appear as a Form 4. Every filing below is therefore tagged with the nature of the underlying transaction, taken from the transaction code reported on the form itself.

Across the 10 insider filings shown, the breakdown is 7 compensation award, 2 open-market sale and 1 open-market purchase. 3 of them involved a discretionary open-market trade; the rest are compensation and administrative mechanics.

What each transaction type means

Compensation award ×7
Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.
Open-market sale ×2
The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.
Open-market purchase ×1
The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.
Form 4 Open-market sale Insider Selling 2026-09-11

AUPH insider Robertson Stephen P. (Chief Legal Officer) sold 11,939 shares (~$190.4K)

Robertson Stephen P., listed as Chief Legal Officer at Aurinia Pharmaceuticals Inc., reported an open-market sale of 11,939 AUPH shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
S Open-market sale 11,939 $15.95 $190.4K
Filing: Form 4 (Insider Transaction) Insider: Robertson Stephen P. (Chief Legal Officer) Shares: 11,939 Est. Value: $190.4K
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-08-25

AUPH insider Robertson Stephen P. (Chief Legal Officer) sold 20,975 shares (~$355.9K)

Robertson Stephen P., listed as Chief Legal Officer at Aurinia Pharmaceuticals Inc., reported an open-market sale of 20,975 AUPH shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
S Open-market sale 20,975 $16.97 $355.9K
Filing: Form 4 (Insider Transaction) Insider: Robertson Stephen P. (Chief Legal Officer) Shares: 20,975 Est. Value: $355.9K
View on SEC EDGAR → Open Filing Document →
Form 4 Compensation award Tax / Compensation Filing 2026-06-08

AUPH insider Form 4 filed for equity award, exercise, or tax withholding

Johnson Craig A (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code Nature Shares Price Value
A Compensation award derivative · Director Stock Option (right to buy) 23,931 — —
Filing: Form 4 (Insider Transaction) Insider: Johnson Craig A (Director)
View on SEC EDGAR → Open Filing Document →
Form 4 Compensation award Tax / Compensation Filing 2026-06-08

AUPH insider Form 4 filed for equity award, exercise, or tax withholding

Goetz Kathleen (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code Nature Shares Price Value
A Compensation award derivative · Director Stock Option (right to buy) 23,931 — —
Filing: Form 4 (Insider Transaction) Insider: Goetz Kathleen (Director)
View on SEC EDGAR → Open Filing Document →
Form 4 Compensation award Tax / Compensation Filing 2026-06-08

AUPH insider Form 4 filed for equity award, exercise, or tax withholding

Nova Tina Susan (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code Nature Shares Price Value
A Compensation award derivative · Director Stock Option (right to buy) 23,931 — —
Filing: Form 4 (Insider Transaction) Insider: Nova Tina Susan (Director)
View on SEC EDGAR → Open Filing Document →
Form 4 Compensation award Tax / Compensation Filing 2026-06-08

AUPH insider Form 4 filed for equity award, exercise, or tax withholding

Bailey Jeffrey Allen (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code Nature Shares Price Value
A Compensation award derivative · Director Stock Option (right to buy) 23,931 — —
Filing: Form 4 (Insider Transaction) Insider: Bailey Jeffrey Allen (Director)
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market purchase Insider Buying 2026-06-02

AUPH insider TANG KEVIN (Director, Chief Executive Officer, 10% Owner) bought 814,606 shares (~$12.46M)

TANG KEVIN, listed as Director, Chief Executive Officer, 10% Owner at Aurinia Pharmaceuticals Inc., reported an open-market purchase of 814,606 AUPH shares in a Form 4 filing. Insider buying is often treated as a bullish signal because company insiders are committing their own capital.

The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.

Transactions reported on this filing
Code Nature Shares Price Value
P Open-market purchase 2,299 $15.35 $35.3K
P Open-market purchase 262,682 $15.31 $4.02M
P Open-market purchase 343,521 $15.28 $5.25M
P Open-market purchase 99 $15.34 $1.5K
P Open-market purchase 206,005 $15.28 $3.15M
J Other transaction derivative · Short Put Options (potential obligation to buy) 10,000 $1.65 $16.5K
Filing: Form 4 (Insider Transaction) Insider: TANG KEVIN (Director, Chief Executive Officer, 10% Owner) Shares: 814,606 Est. Value: $12.46M
View on SEC EDGAR → Open Filing Document →
Form 4 Compensation award Tax / Compensation Filing 2026-05-20

AUPH insider Form 4 filed for equity award, exercise, or tax withholding

Robertson Stephen P. (Chief Legal Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code Nature Shares Price Value
A Compensation award 115,541 — —
Filing: Form 4 (Insider Transaction) Insider: Robertson Stephen P. (Chief Legal Officer) Shares: 115,541
View on SEC EDGAR → Open Filing Document →
Form 4 Compensation award Tax / Compensation Filing 2026-05-20

AUPH insider Form 4 filed for equity award, exercise, or tax withholding

Hearne Michael S (Chief Financial Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code Nature Shares Price Value
A Compensation award 116,144 — —
A Compensation award derivative · Employee Stock Option (right to buy) 70,230 — —
Filing: Form 4 (Insider Transaction) Insider: Hearne Michael S (Chief Financial Officer) Shares: 116,144
View on SEC EDGAR → Open Filing Document →
Form 4 Compensation award Tax / Compensation Filing 2026-05-20

AUPH insider Form 4 filed for equity award, exercise, or tax withholding

Cole Ryan (Chief Operating Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code Nature Shares Price Value
A Compensation award 116,144 — —
A Compensation award derivative · Employee Stock Option (right to buy) 70,230 — —
Filing: Form 4 (Insider Transaction) Insider: Cole Ryan (Chief Operating Officer) Shares: 116,144
View on SEC EDGAR → Open Filing Document →
Proposed Insider Sales 6 · Form 144

A Form 144 is a notice of intent to sell restricted or control securities. It is not a record that anything was sold. Aurinia Pharmaceuticals Inc. has 6 such notices in this period.

The distinction matters because a Form 144 is frequently reported as though it were a completed insider sale. The filer may sell all of the shares covered, some of them, or none at all, and there is no obligation to update the notice either way. A sale that is actually executed by an officer or director shows up separately on a Form 4, which is the filing to check before treating a proposed sale as a real one.

Form 144 Proposed Insider Sale 2026-08-21

AUPH Form 144 filed for proposed insider sale by Stephen P. Robertson (47,000 shares) ~$719.1K

Stephen P. Robertson filed a Form 144 with the SEC indicating intent to sell AUPH (Aurinia Pharmaceuticals Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: Stephen P. Robertson Shares: 47,000 Est. Value: $719.1K
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2026-06-05

AUPH Form 144 filed for proposed insider sale by GREGORY KEENAN (9,593 shares) ~$158.5K

GREGORY KEENAN filed a Form 144 with the SEC indicating intent to sell AUPH (Aurinia Pharmaceuticals Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: GREGORY KEENAN Shares: 9,593 Est. Value: $158.5K
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2026-06-04

AUPH Form 144 filed for proposed insider sale by GREGORY KEENAN (25,000 shares) ~$408.4K

GREGORY KEENAN filed a Form 144 with the SEC indicating intent to sell AUPH (Aurinia Pharmaceuticals Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: GREGORY KEENAN Shares: 25,000 Est. Value: $408.4K
View on SEC EDGAR → Open Filing Document →
Form 144 Large Proposed Insider Sale 2026-06-02

AUPH Form 144 filed for proposed insider sale by GREGORY KEENAN (25,000 shares) ~$54.10M

GREGORY KEENAN filed a Form 144 with the SEC indicating intent to sell AUPH (Aurinia Pharmaceuticals Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4. The proposed dollar value is large enough to merit attention.

Filing: Form 144 (Proposed Sale Notice) Insider: GREGORY KEENAN Shares: 25,000 Est. Value: $54.10M
View on SEC EDGAR → Open Filing Document →
Form 144 Large Proposed Insider Sale 2026-05-11

AUPH Form 144 filed for proposed insider sale by PETER GREENLEAF (3,136,201 shares) ~$49.68M

PETER GREENLEAF filed a Form 144 with the SEC indicating intent to sell AUPH (Aurinia Pharmaceuticals Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4. The proposed dollar value is large enough to merit attention.

Filing: Form 144 (Proposed Sale Notice) Insider: PETER GREENLEAF Shares: 3,136,201 Est. Value: $49.68M
View on SEC EDGAR → Open Filing Document →
Form 144 Large Proposed Insider Sale 2026-05-11

AUPH Form 144 filed for proposed insider sale by MATTHEW MAXWELL DONLEY (717,688 shares) ~$11.37M

MATTHEW MAXWELL DONLEY filed a Form 144 with the SEC indicating intent to sell AUPH (Aurinia Pharmaceuticals Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4. The proposed dollar value is large enough to merit attention.

Filing: Form 144 (Proposed Sale Notice) Insider: MATTHEW MAXWELL DONLEY Shares: 717,688 Est. Value: $11.37M
View on SEC EDGAR → Open Filing Document →
Material Events 3 · Form 8-K

An 8-K reports a material event in the window between scheduled reports. There are 3 in this period for Aurinia Pharmaceuticals Inc. Each 8-K names the item number it is filed under, and that number is the fastest way to tell a routine disclosure from a consequential one.

Item 2.02 is an earnings release, Item 5.02 is a change of directors or officers, and Item 1.01 or 2.01 covers a material agreement or a completed acquisition. Item 7.01 and Item 8.01 are the general-purpose disclosure items and carry no fixed meaning on their own.

Form 8-K Material Company Update 2026-08-19

AUPH filed 8-K — material company event

Aurinia Pharmaceuticals Inc. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)
View on SEC EDGAR → Open Filing Document →
Form 8-K Material Company Update 2026-08-06

AUPH filed 8-K — material company event

Aurinia Pharmaceuticals Inc. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)
View on SEC EDGAR → Open Filing Document →
Form 8-K Material Company Update 2026-06-04

AUPH filed 8-K — material company event

Aurinia Pharmaceuticals Inc. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)
View on SEC EDGAR → Open Filing Document →
Periodic Reports 1 · Forms 10-K and 10-Q

The periodic reports are where the audited and reviewed financial statements live. This period contains 1 quarterly report (10-Q) for Aurinia Pharmaceuticals Inc.

The two are not equivalent in weight. A 10-K is audited by an external firm and includes the full risk factor disclosure, business description and management discussion; a 10-Q is unaudited, reviewed rather than examined, and much shorter. When a figure in a quarterly report is later revised, the annual report is usually where the correction appears.

An amended report — 10-K/A or 10-Q/A — restates or corrects something in the original filing, and is worth reading against the version it replaces.

Form 10-Q Quarterly Report 2026-08-06

AUPH filed Quarterly Report (10-Q)

Aurinia Pharmaceuticals Inc. filed its quarterly report with the SEC. This report includes unaudited financial statements and management discussion for the quarter.

Filing: 10-Q (Quarterly Report)
View on SEC EDGAR → Open Filing Document →

How we classify Aurinia Pharmaceuticals Inc.'s filings

Straight from EDGAR

Each displayed record links to an original source document. StrongBuyAnalytics provides navigation and brief excerpts or summaries, not the filing itself. Parsing may omit context or contain errors, so read the original document in full.

Transaction codes, not guesswork

The nature shown on each insider filing comes from the transaction code the filer entered on the form itself — P for an open-market purchase, A for a compensation award, F for shares withheld to pay tax, M for an option exercise. Where one filing contains several codes, the transaction table lists them line by line.

Why the distinction matters

Insider activity is routinely summarised as buying or selling, which flattens together decisions that mean very different things. Shares withheld for tax on a vesting grant are an automatic administrative step; shares bought on the open market are someone committing their own money at the current price.

What this page does not tell you

A filing records what happened, not why. Form 4 does not always disclose whether a sale was executed under a pre-arranged Rule 10b5-1 plan, and no single filing is a basis for a decision on AUPH. Read these alongside the fundamentals rather than in isolation.

Frequently Asked Questions — AUPH SEC Filings

More Tools for AUPH

AUPH Full Stock Analysis AUPH Live Chart Institutional Ownership Earnings Calendar Options Flow Scanner Semiconductor Demand Zone Tracker Sector Scanner Browse All Stocks

Want deeper AUPH analysis?

View valuation, growth metrics, the rule-based stock-page score, demand zones, peer comparison, and more — all on the AUPH stock analysis page.

AUPH Full Analysis
Publisher, sources & limitations — September 15, 2026. StrongBuyAnalytics provides navigation and brief excerpts or summaries for educational use. Original filings remain at SEC EDGAR or other displayed source links; StrongBuyAnalytics does not author them. Filing dates are source dates, not publication dates for this page. Coverage can be delayed, incomplete, amended, or unavailable because of SEC/source availability, parsing, caching, or outages. Verify every material statement in the original filing.
Data Sources · Methodology · AI Disclosure · Corrections Policy · Disclaimer